newsfilter
← Latest News
GlobeNewswire·

MapLight Therapeutics Announces $150 Million Private Placement Financing

  • MapLight Therapeutics (NASDAQ: MPLT) entered a private placement financing (PIPE) agreement to raise approximately $150 million in gross proceeds before fees & expenses.
  • The company is selling 9,197,887 common stock shares at $11.38 per share & pre-funded warrants for up to 3,983,168 shares at $11.3799 per warrant.
  • Pre-funded warrants have an exercise price of $0.0001, are immediately exercisable, & do not expire.
  • The PIPE is expected to close on August 14, 2026, subject to customary closing conditions.
  • Proceeds will primarily fund the ML-007C-MA VISTA Phase 2 Alzheimer's study & ZEPHYR-2 Phase 3 schizophrenia study, plus working capital & general corporate purposes.
  • MapLight plans an FDA End-of-Phase 2 meeting to discuss the schizophrenia Phase 3 trial design to support a future New Drug Application submission.
  • Existing cash of $351.3 million as of June 30, 2026, combined with PIPE proceeds, is expected to fund ML-007C-MA development through 2028.
  • Morgan Stanley, Jefferies, Leerink Partners, & Stifel are acting as placement agents for the transaction.
  • Cooley LLP served as counsel to MapLight, while Latham & Watkins LLP represented the placement agents.
  • Securities sold in the PIPE are unregistered under the Securities Act of 1933, though MapLight will file a registration statement for their resale with the SEC.